Unexpected protective role for Toll-like receptor 3 in the arterial wall
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The critical role of Toll-like receptors (TLRs) in mammalian host defense has been extensively explored in recent years. The capacity of about 10 TLRs to recognize conserved patterns on many bacterial and viral pathogens is remarkable. With so few receptors, cross-reactivity with self-tissue components often occurs. Previous studies have frequently assigned detrimental roles to TLRs, in particular to TLR2 and TLR4, in immune and cardiovascular disease. Using human and murine systems, we have investigated the consequence of TLR3 signaling in vascular disease. We compared the responses of human atheroma-derived smooth muscle cells (AthSMC) and control aortic smooth muscle cells (AoSMC) to various TLR ligands. AthSMC exhibited a specific increase in TLR3 expression and TLR3-dependent functional responses. Intriguingly, exposure to dsRNA in vitro and in vivo induced increased expression of both pro- and anti-inflammatory genes in vascular cells and tissues. Therefore, we sought to assess the contribution of TLR3 signaling in vivo in mechanical and hypercholesterolemia-induced arterial injury. Surprisingly, neointima formation in a perivascular collar-induced injury model was reduced by the systemic administration of the dsRNA analog Poly(I:C) in a TLR3-dependent manner. Furthermore, genetic deletion of TLR3 dramatically enhanced the development of elastic lamina damage after collar-induced injury. Accordingly, deficiency of TLR3 accelerated the onset of atherosclerosis in hypercholesterolemic ApoE −/− mice. Collectively, our data describe a protective role for TLR signaling in the vessel wall.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895 · cited 10×
“Treatment with Poly(I:C) reduced the occurrence of the elastic lamina breaks in TLR3 mice, suggesting that, in the absence of TLR3, other sensors of dsRNA such as melanoma differentiation-associated protein 5 (MDA5) can mediate protection (4).”
BackgroundInfluentialRecognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630
Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J.-M., & Hoffmann, J. A. (1996) · Cell · doi:10.1016/s0092-8674(00)80172-5 · Cited by 4,043
Innate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434 · cited 1×
“Charles Janeway’s realization that innate immunity triggers adaptive responses (immunology’s “dirty” secret) has catalyzed research to analyze innate immune sensors and their effector pathways (3).”
BackgroundChromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J., & Marshak-Rothstein, A. (2002) · Nature · doi:10.1038/416603a · Cited by 1,900 · cited 10×
“Prinz M, et al. (2006) Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis.”
BackgroundInfluentialStewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1836 · Cited by 1,513 · cited 6×
“Previous studies have frequently assigned detrimental roles to TLRs, in particular to TLR2 and TLR4, in immune and cardiovascular disease.”
BackgroundInfluentialmRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062
Michelsen, K. S., Wong, M. H., Shah, P. K., Zhang, W., Yano, J., Doherty, T. M., Akira, S., Rajavashisth, T. B., & Arditi, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403249101 · Cited by 1,019 · cited 1×
“In contrast to current concepts, TLRs are not always detrimental in vascular disease (7, 10, 25), but they can be relevant in repair mechanisms within the vessel wall.”
BackgroundMidwood, K., Sacre, S., Piccinini, A. M., Inglis, J., Trebaul, A., Chan, E., Drexler, S., Sofat, N., Kashiwagi, M., Orend, G., et al. (2009) · Nature Medicine · doi:10.1038/nm.1987 · Cited by 703 · cited 6×
“Previous studies have frequently assigned detrimental roles to TLRs, in particular to TLR2 and TLR4, in immune and cardiovascular disease.”
BackgroundInfluentialHMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses
Yanai, H., Ban, T., Wang, Z., Choi, M. K., Kawamura, T., Negishi, H., Nakasato, M., Lu, Y., Hangai, S., Koshiba, R., et al. (2009) · Nature · doi:10.1038/nature08512 · Cited by 688 · cited 1×
“Endogenous RNA released by damaged tissue or necrotic cells is able to induce TLR3 expression and signaling (31), whereas the alarmin high-mobility group protein B1 sensitizes TLR3 to the recognition of RNA (32).”
BackgroundBjörkbacka, H., Kunjathoor, V. V., Moore, K. J., Koehn, S., Ordija, C. M., Lee, M. A., Means, T., Halmen, K., Luster, A. D., Golenbock, D. T., et al. (2004) · Nature Medicine · doi:10.1038/nm1008 · Cited by 634
Modulation of atherosclerosis in mice by Toll-like receptor 2
Mullick, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25482 · Cited by 549
Axtell, R. C., de Jong, B. A., Boniface, K., van der Voort, L. F., Bhat, R., De Sarno, P., Naves, R., Han, M., Zhong, F., Castellanos, J. G., et al. (2010) · Nature Medicine · doi:10.1038/nm.2110 · Cited by 534 · cited 3×
“The mechanism of such heterogeneity in therapeutic response has been partially elucidated by Lawrence Steinman, who showed the effectiveness of IFNβ in Th1/IFNγdependent, but not in Th17/IL-17-dependent, EAE (37).”
BackgroundVirus-induced atherosclerosis.
Fabricant, C. G., Fabricant, J., Litrenta, M. M., & Minick, C. R. (1978) · The Journal of experimental medicine · doi:10.1084/jem.148.1.335 · Cited by 508
TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events
Cavassani, K. A., Ishii, M., Wen, H., Schaller, M. A., Lincoln, P. M., Lukacs, N. W., Hogaboam, C. M., & Kunkel, S. L. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081370 · Cited by 449 · cited 1×
“, rheumatoid arthritis (28) and sepsis (29).”
Deletion of TLR5 results in spontaneous colitis in mice
Vijay-Kumar, M., Sanders, C. J., Taylor, R. T., Kumar, A., Aitken, J. D., Sitaraman, S. V., Neish, A. S., Uematsu, S., Akira, S., Williams, I. R., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33084 · Cited by 420
Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis
Rachmilewitz, D., Karmeli, F., Takabayashi, K., Hayashi, T., Leider-Trejo, L., Lee, J., Leoni, L. M., & Raz, E. (2002) · Gastroenterology · doi:10.1053/gast.2002.32994 · Cited by 384
Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis
Prinz, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26078 · Cited by 380
Monaco, C., Andreakos, E., Kiriakidis, S., Mauri, C., Bicknell, C., Foxwell, B., Cheshire, N., Paleolog, E., & Feldmann, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401060101 · Cited by 348 · cited 2×
“We have previously shown that a mixed cell population of cells isolated from human atheroma is able to spontaneously produce TNF, IL-1, and IFNγ (18).”
BackgroundMethodSelf-citationRoelofs, M. F., Joosten, L. A. B., Abdollahi‐Roodsaz, S., Van Lieshout, A. W. T., Sprong, T., van den Hoogen, F. H., Van Den Berg, W. B., & Radstake, T. R. D. J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21278 · Cited by 334 · cited 1×
“, rheumatoid arthritis (28) and sepsis (29).”
Vessel-Specific Toll-Like Receptor Profiles in Human Medium and Large Arteries
Pryshchep, O., Ma-Krupa, W., Younge, B. R., Goronzy, J. J., & Weyand, C. M. (2008) · Circulation · doi:10.1161/circulationaha.108.789172 · Cited by 323
Booth, R. F. G., Martin, J. F., Honey, A. C., Hassall, D. G., Beesley, J. E., & Moncada, S. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90109-3 · Cited by 322
Toll‐like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators
Bsibsi, M., Persoon‐Deen, C., Verwer, R. W. H., Meeuwsen, S., Ravid, R., & Van Noort, J. M. (2006) · Glia · doi:10.1002/glia.20328 · Cited by 297 · cited 1×
“The production of protective mediators, including IL-10, following TLR3 activation has been reported (40).”
BackgroundIFNs activate toll-like receptor gene expression in viral infections
Miettinen, M., Sareneva, T., Julkunen, I., & Matikainen, S. (2001) · Genes & Immunity · doi:10.1038/sj.gene.6363791 · Cited by 282 · cited 1×
“As viral genome-dependent induction of TLR3 is blocked by neutralizing type I interferons or their receptor (30), Poly(I:C)-inducedup-regulationofTLR3 inour systems may also be due to autocrine IFN signaling.”
BackgroundNiessner, A., Sato, K., Chaikof, E. L., Colmegna, I., Goronzy, J. J., & Weyand, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.642801 · Cited by 243
Naghavi, M., Wyde, P., Litovsky, S., Madjid, M., Akhtar, A., Naguib, S., Siadaty, M. S., Sanati, S., & Casscells, W. (2003) · Circulation · doi:10.1161/01.cir.0000048190.68071.2b · Cited by 239 · cited 1×
“The pathogenic viral mechanisms reported include cytolytic (35) and immunomediated effects (36).”
BackgroundGoossens, P., Gijbels, M. J. J., Zernecke, A., Eijgelaar, W., Vergouwe, M. N., van der Made, I., Vanderlocht, J., Beckers, L., Buurman, W. A., Daemen, M. J. A. P., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.06.008 · Cited by 225 · cited 1×
“Whether the vasculoprotection provided by TLR3 is dependent on the production of type I IFNs is uncertain because IFNβ therapy has shown conflicting results in animal models of atherosclerosis (38, 39).”
ResultMullick, A. E., Soldau, K., Kiosses, W. B., Bell, T. A., Tobias, P. S., & Curtiss, L. K. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071096 · Cited by 223 · cited 1×
“In atherosclerosis, TLR2 expression has been reported at very early stages of disease on endothelial cells in atherosclerosis-susceptible regions of the aorta (16).”
BackgroundUnexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis
Marta, M., Andersson, Å., Isaksson, M., Kämpe, O., & Lobell, A. (2008) · European Journal of Immunology · doi:10.1002/eji.200737187 · Cited by 198 · cited 3×
“The mechanism of such heterogeneity in therapeutic response has been partially elucidated by Lawrence Steinman, who showed the effectiveness of IFNβ in Th1/IFNγdependent, but not in Th17/IL-17-dependent, EAE (37).”
BackgroundChoe, J.-Y., Crain, B., Wu, S. R., & Corr, M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021850 · Cited by 195
Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis
Monaco, C., Gregan, S. M., Navin, T. J., Foxwell, B. M. J., Davies, A. H., & Feldmann, M. (2009) · Circulation · doi:10.1161/circulationaha.109.851881 · Cited by 162 · cited 2×
“TLR2 blockade reduces both cytokines and destructive matrix metalloproteinase enzymes, suggesting that a yet-to-be-identified TLR2 agonist may be present in human atherosclerotic plaques and that it may be a useful therapeutic target (25).”
BackgroundSelf-citationActivation of toll-like receptor 3 protects against DSS-induced acute colitis
Vijay-Kumar, M., Wu, H., Aitken, J., Kolachala, V. L., Neish, A. S., Sitaraman, S. V., & Gewirtz, A. T. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20142 · Cited by 137
Aumeunier, A., Grela, F., Ramadan, A., Pham Van, L., Bardel, E., Gomez Alcala, A., Jeannin, P., Akira, S., Bach, J.-F., & Thieblemont, N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011484 · Cited by 132 · cited 1×
“The administration of agonists of TLR3, TLR4, TLR7, and TLR9 prevents spontaneous diabetes in nonobese diabetic mice (11), whereas TLR4 abrogation increases EAE (12).”
BackgroundUpdate on statin-mediated anti-inflammatory activities in atherosclerosis
Montecucco, F., & Mach, F. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0150-y · Cited by 101 · cited 1×
“The therapeutic advantage of statins over other lipid-lowering strategies (2) supports a complex interaction between risk factors, including lipid metabolism and inflammation.”
BackgroundKoga, N., Suzuki, J., Kosuge, H., Haraguchi, G., Onai, Y., Futamatsu, H., Maejima, Y., Gotoh, R., Saiki, H., Tsushima, F., et al. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000145015.23656.e4 · Cited by 100 · cited 1×
“The B7 family members PDL1 and PDL2, which are augmented after TLR3 stimulation, may also contribute to vascular protection (41, 42).”
BackgroundThe Microtubule Regulator Stathmin Is an Endogenous Protein Agonist for TLR3
Bsibsi, M., Bajramovic, J. J., Vogt, M. H. J., van Duijvenvoorden, E., Baghat, A., Persoon-Deen, C., Tielen, F., Verbeek, R., Huitinga, I., Ryffel, B., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902419 · Cited by 88 · cited 1×
“Interestingly, stathmin, a protein with a regulatory function on microtubule assembly that is up-regulated in brain injury, has been described as a candidate TLR3 agonist, linked to the induction of a neuroprotective gene profile (33).”
BackgroundYang, X. T., Murthy, V., Schultz, K., Tatro, J. B., Fitzgerald, K. A., & Beasley, D. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00252.2006 · Cited by 63 · cited 1×
“SMC have been previously shown to respond to a variety of TLR agonists (17).”
BackgroundTLR-mediated induction of negative regulatory ligands on dendritic cells
Gröschel, S., Piggott, K., Vaglio, A., Ma-Krupa, W., Singh, K., Goronzy, J. J., & Weyand, C. M. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0310-x · Cited by 40 · cited 1×
“The B7 family members PDL1 and PDL2, which are augmented after TLR3 stimulation, may also contribute to vascular protection (41, 42).”
BackgroundZhang, L.-N., Velichko, S., Vincelette, J., Fitch, R. M., Vergona, R. A., Sullivan, M. E., Croze, E., & Wang, Y. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.019 · Cited by 37
Ahmad, U., Ali, R., Lebastchi, A. H., Qin, L., Lo, S.-F. L., Yakimov, A. O., Khan, S. F., Choy, J. C., Geirsson, A., Pober, J. S., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902283 · Cited by 37
Krebs, P., Scandella, E., Bolinger, B., Engeler, D. S., Miller, S., & Ludewig, B. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.141846 · Cited by 19 · cited 1×
“The pathogenic viral mechanisms reported include cytolytic (35) and immunomediated effects (36).”
Background
Cited by
Atherosclerosis: current pathogenesis and therapeutic options
Weber, C., & Noels, H. (2011) · Nature Medicine · doi:10.1038/nm.2538 · Cited by 2,203
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
Toll-like receptor 4 (TLR4): new insight immune and aging
Kim, H.-J., Kim, H., Lee, J.-H., & Hwangbo, C. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00383-3 · Cited by 450
Metadata
- Authors
- Cole, J. E., Navin, T. J., Cross, A. J., Goddard, M. E., Alexopoulou, L., Mitra, A. T., Davies, A. H., Flavell, R. A., Feldmann, M., & Monaco, C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-01-10
- Volume
- 108
- Issue
- 6
- Pages
- 2372-2377
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1983838712
- Cited by
- 170
- References
- 42
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.